Show simple item record

dc.contributor.authorLópez-Muñoz, F.
dc.contributor.authorGarcía-García, P.
dc.contributor.authorÁlamo González, C
dc.date.accessioned2018-06-26T15:34:49Z
dc.date.available2018-06-26T15:34:49Z
dc.date.issued2014-06
dc.identifier.citationCecilio Álamo, Francisco López-Muñoz & Pilar García-García (2014) The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder, Expert Review of Neurotherapeutics, 14:6, 593-605, DOI: 10.1586/14737175.2014.915741es
dc.identifier.issn1734-8803
dc.identifier.urihttp://hdl.handle.net/20.500.12020/764
dc.description.abstractThe majority of patients with bipolar disorder spend a lot of time in depressive episodes that impose a great burden on patients, caregivers, and society and accounts for the largest part of the morbidity-mortality of the illness. Lurasidone is an atypical antipsychotic with a potent binding affinity as antagonist for D2, 5-HT2A, 5-HT7, and partial agonist at 5-HT1A receptors. Affinity for other receptors as H1 and muscarinic were negligible. Lurasidone was approved in 2010 for the treatment of schizophrenia and recently, 2013, for bipolar depression in monotherapy and an adjunct to lithium or valproate. Clinical trials have established that lurasidone adjuvant to lithium or valproate has more efficacy than the placebo and is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or the QT interval. Additional studies are desirable to know the clinical profile of lurasidone in long-term treatment, in patients with bipolar II disorders, and versus other antipsychotic agents.es
dc.language.isoenes
dc.publisherTaylor & Francises
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleThe effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorderes
dc.typearticlees
dc.identifier.doi10.1586/14737175.2014.915741
dc.issue.number6es
dc.journal.titleExpert Review of Neurotherapeuticses
dc.page.initial593es
dc.page.final605es
dc.rights.accessRightsopenAccesses
dc.subject.areaPsicologíaes
dc.subject.keywordAdjunctive therapyes
dc.subject.keywordAtypical antipsychoticses
dc.subject.keywordBipolar disorderes
dc.subject.keywordLithiumes
dc.subject.keywordLurasidonees
dc.subject.keywordValproatees
dc.subject.unesco61 Psicologíaes
dc.volume.number14es


Files in this item

File/sSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional